Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle of bortezomib. Most of them had advanced dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Eom, Ki-Seong, Kim, Seok Jin, Lee, Je-Jung, Suh, Cheolwon, Kim, Jin Seok, Yoon, Sung-Soo, Kim, Byung Soo, Kang, Hye Jin, Choi, Young Jin, Kim, Chul Soo, Kim, Yang Soo, Kwak, Jae-Yong, Kim, Yoo Jin, Joo, Young Don, Mun, Yeung-Chul, Jo, Deog Yeon, Park, Joon Seong, Park, Chi-Young, Kim, Sung-Hyun, Min, Chang-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094867/
https://www.ncbi.nlm.nih.gov/pubmed/25050331
http://dx.doi.org/10.1155/2014/245247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094867/
https://www.ncbi.nlm.nih.gov/pubmed/25050331
http://dx.doi.org/10.1155/2014/245247

Ejemplares similares